SBWire

Atherosclerosis Partnering 2009-2014 provides understanding and access to the atherosclerosis partnering deals and agreements entered into by the worlds leading healthcare companies.

Laboratoires Thea S.A. - Product Pipeline Review - 2014

Amyotrophic lateral sclerosis (ALS), often referred to as "Lou Gehrig's Disease," is a rare, but fatal, progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord. ALS severely impacts physical functioning and initially presents with muscle twitching, weakness in an arm or leg, or with slurring of speech. Eventually, people with ALS lose their ability to control the muscles needed to move, speak, eat, and breathe, which ultimately leads to death. The progressively degenerative course of the condition is a great burden for both patients and caregivers, as well as for society.

Insomnia - Pipeline Review, H1 2014

Acute Heart Failure - Pipeline Review, H1 2014

Polycystic Ovarian Syndrome - Pipeline Review, H1 2014

Agenus, Inc. - Product Pipeline Review - 2014

Biogen Idec Inc. - Product Pipeline Review - 2014

Advanced Cell Technology, Inc. - Product Pipeline Review - 2014

Mertiva AB - Product Pipeline Review - 2014

BioCryst Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Meningococcal Meningitis - Pipeline Review, H1 2014

Spasticity - Pipeline Review, H1 2014

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

Iron Deficiency Anemia - Pipeline Review, H1 2014

GlobalData's clinical trial report, "Diabetic Ketoacidosis Global Clinical Trials Review, H1, 2014" provides data on the Diabetic Ketoacidosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Ketoacidosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Ketoacidosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Indolent Lymphoma - Pipeline Review, H1 2014

The Genetic Disorders Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter genetic disorders partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Animal Antimicrobials and Antibiotics Market by Products (Tetracyclines, Penicillins, Sulfonamides, Aminoglycosides), Animals (Dog, Poultry, Swine), Mode Of Delivery (Premixes, Oral Powders and Solutions, Injections) - Global Forecasts to 2018

Animal Parasiticides Market by Product (Endoparasiticides, Ectoparasiticides, Endectocides, Oral Liquids, Tablets, Injectables, Sprays, Pour On, Spot On, Collars, Ear Tags), Animal (Dogs, Cats, Cattle, Pigs, Sheep & Goats) - Global Forecast to 2018

Peptic Ulcers - Pipeline Review, H1 2014

Vitiligo - Pipeline Review, H1 2014

Multiple Sclerosis - Pipeline Review, H1 2014

Receptos, Inc. - Product Pipeline Review - 2014

Dystonia - Pipeline Review, H1 2014